GW Pharmaceuticals and Bayer signed GW’s first ever commercial deal. The agreement granted Bayer exclusive UK marketing rights to Sativex®, GW’s cannabis-based medicinal extract product for multiple sclerosis and neuropathic pain indications. This article focuses on the consequence of the deal on both parties in view of recent company events, business strategies and UK legislation.